Other antiviral compounds

Version vom 23. Juni 2020, 12:59 Uhr

32248766 2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19
32429580 2020. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).
32423027 2020. COVID-19: An Update About the Discovery Clinical Trial.
32023685 2020. [Potential antiviral therapeutics for 2019 Novel Coronavirus].
32432977 2020. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.
32501538 2020. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.
32495848 2020. Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.

Amantadine
32361028 ä. Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ?
32361100 2020. Amantadine as a drug to mitigate the effects of COVID-19
32176361 2020. Potentially repurposing adamantanes for COVID-19
32495926 2020. Does amantadine have a protective effect against COVID-19?
32436995 2020. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.

Arbidol retarget influenza
32373347 2020. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
32360231 ä. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ?
32171872 ä. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
32388937 2020. [Real-world efficacy and safety of lopinavir/ritonavir and arbidol in treating with COVID-19 : an observational cohort study].
32510169 2020. A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19.
32496210 2020. Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19.

Auranofin
32442105 2020. The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.

Favipiravir
32401463 2006. Favipiravir
32346491 ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
32246834 2020. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection
32350860 2020. Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2
32360327 ä. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence
32475019 2020. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.

Niclosamide
32125140 ä. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
32361588 2020. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19

Sofosbuvir
32387040 ä. Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
32420958 2020. Sofosbuvir as a potential option for the treatment of COVID-19.

Umifenovir
32344167 ä. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study

Anti HCV nucleotides
32119961 2020. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

Ritonavir
32344308 2020. Suggesting Ritonavir against COVID-19/SARS-CoV-2

Didanosine
32291351 2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data

Tilorone
32215760 2020. Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond
32205350 2020. Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses

Darunavir
32325127 2020. Darunavir does not prevent SARS-CoV-2 infection in HIV patients

NHC
32253226 ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
32253226 ä. (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Ribavirin
32227493 ä. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID?19

16621037 2006. (x)Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin Nelfinavir
32374457 2020. The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections

---ivermectin
32458795 2020. Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2.

beta ketoamides
32045235 ä. ?-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment

Novirinn
32283177 ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections

some lipids
32229155 2020. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?

phenantroids
20727913 2010. (x)Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus

-
31073993 2019. (x)Synthesis and anti?coronavirus activity of a series of 1?thia?4?azaspiro 4 5 decan?3?one derivatives
28945945 2017. Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses